Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease


A modified primate model of Parkinson's disease was developed to assess the effectiveness of various agents that act via dopamine, acetylcholine, serotonin or glutamate systems. Using a MPTP dosing regimen a reversible parkinsonian-like syndrome was produced in the marmoset. An obvious advantage of such a protocol is that it allows multiple drug studies to be undertaken in animals, without the need for prolonged anti-parkinsonian therapy to maintain their health. Results show that dopamine D2 agonists (bromocriptine, quinpirole, N,N-dipropyl,A,5,6-DTN, (+)3PPP and PHNO), anti-muscarinics (atropine, scopolamine and benztropine), in addition tol-DOPA and nomifensine, all reduced the bradykinesia induced by MPTP. The D1 agonist SKF-38393 and the partial dopamine agonist (−)3PPP were both ineffective. Finally, agents with potential therapeutic use in Parkinson's disease were also tested. However, a glutamate antagonist (MK801) and three serotonin antagonists (ritanserin, ketanserin and ICI 170,809) were all unable to alter the MPTP effects, at the doses used in our study.

DOI: 10.1007/BF02244093

6 Figures and Tables

Citations per Year

2,100 Citations

Semantic Scholar estimates that this publication has 2,100 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Close1990EffectsOC, title={Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease}, author={Steve P. Close and Peter J. Elliott and Antoinette Hayes and Andrew S. Marriott}, journal={Psychopharmacology}, year={1990}, volume={102}, pages={295-300} }